Menu
Search
|

Menu

Close
X

Assembly Biosciences Inc ASMB.OQ (NASDAQ Stock Exchange Capital Market)

56.82 USD
-- (--)
As of Feb 16
chart
Previous Close 56.82
Open --
Volume --
3m Avg Volume 57,991
Today’s High --
Today’s Low --
52 Week High 58.57
52 Week Low 18.60
Shares Outstanding (mil) 17.36
Market Capitalization (mil) 613.14
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
3
FY16
0
FY15
0
EPS (USD)
FY17
-1.591
FY16
-2.569
FY15
-1.879
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
201.45
5.77
Price to Book (MRQ)
vs sector
10.84
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-45.44
14.43
Return on Equity (TTM)
vs sector
-64.48
16.13

EXECUTIVE LEADERSHIP

William Ringo
Independent Non-Executive Chairman of the Board, Since 2015
Salary: --
Bonus: --
Derek Small
President, Chief Executive Officer, Director, Since 2015
Salary: $160,416.00
Bonus: $116,667.00
David Barrett
Chief Financial Officer, Chief Operating Officer, Since 2015
Salary: $299,358.00
Bonus: $150,000.00
Thomas Rollins
Chief Development Officer, Since 2017
Salary: --
Bonus: --
Alan Lewis
Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11711 N Meridian St Ste 310
CARMEL   IN   46032-4549

Phone: +1212.5544388

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

SPONSORED STORIES